Cell Lung Cancer

Glasgow prognostic score appeared associated with survival among patients with small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide, according to study results.

A study of more than 20,000 patients with non-small cell lung cancer in Korea showed improvements in survival outcomes across all stages of disease between 2010 and 2020 amid increased use of molecular testing and targeted treatments.

Osimertinib conferred a statistically significant and clinically meaningful improvement in OS compared with placebo among patients with early-stage EGFR-mutated non-small cell lung cancer, according to the agent’s manufacturer.

A preoperative biopsy procedure did not raise the risk for tumor spread through airspaces among patients with resected stage I non-small cell lung cancer, according to a study published in CHEST.

The FDA issued a complete response letter to Spectrum Pharmaceuticals indicating it could not approve the company’s new drug application that sought approval of poziotinib as treatment for certain patients with lung cancer.

The FDA approved durvalumab with gemcitabine and cisplatin for adults with locally advanced or metastatic biliary tract cancer.

The FDA granted accelerated approval to lurbinectedin for adults with metastatic small cell lung cancer that progressed on or after platinum-based chemotherapy.